Company intelligence / Profile preview

Dianomi Therapeutics

Madison, Wisconsin, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Dianomi has demonstrated promising preclinical results with its interleukin-1 receptor antagonist program utilizing the MCM platform, showing improved sustained drug delivery and efficacy in animal models. The company is aiming to enter Phase 1 trials for ARDS in COVID-19 and progressing osteoarthritis and gout programs[2][3].

Therapeutic areas: PulmonologyNeurologyImmunologyRheumatology
Modalities: BiologicSmall moleculeNucleic acid therapyProteinmRNA-based drugs
Industry: Biotech

Partnerships

Ligand Pharmaceuticals[4][7]Wisconsin Alumni Research Foundation (WARF)[2][7]

Beyond the preview

Go deeper on Dianomi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dianomi Therapeutics.

Explore the full profile